戴啟明醫(yī)師-預(yù)覽頁(yè)
【正文】 cacy of pharmacological treatments for patients with bleeding peptic ulcers exhibiting highrisk stigmata (Forrest IaIIb). Three groups of treatment were assessed: protonpump inhibitors given as highdose bolus followed by intravenous constant infusion (4080 mg and at least 6 mg/h), highdose oral protonpump inhibitors (at least twice the standard dosage), nonhighdose protonpump inhibitors (other protonpump inhibitors dosing schedules) Mixedeffect models were used to determine rate differences between treatment and control groups. 6. Citations Nonhighdose protonpump inhibitor regimens ? 20–40 mg bolus every 3–6 h ? 40 mg bolus followed by 80 mg/day continuous infusion ? 40 mg q12 h for 3 days ? 80 mg bolus followed by 40 mg q12 ? 40 mg q12 h for 2 days followed by 40 mg/day oral ? Results: highdose bolus followed by intravenous constant infusion =significantly decreases ulcer rebleeding, surgery and mortality highdose oral protonpump inhibitors = reduced rebleeding but not surgery or mortality nonhighdose protonpump inhibitors =reduced rebleeding, surgery and mortality 8. Conclusion ? PPIs: (vs. placebo) intravenous 80 mg bolus and then 8 mg/h PH值 6，有助於血塊的形成，降低再出血率，手術(shù)和死亡率 ? 較低劑量的 PPIs也可能有效 ? 但 40mg qd or bid vs. highdose ?? Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer Julapalli V et al. Dig Dis Sci 2
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1